2022: The End Of The US Price Negotiation Debate?
Executive Summary
The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.
You may also be interested in...
Drug Price Increases Accelerate: ‘Political Opportunism’ In A Return To Business As Usual?
Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.
Democratic Drug Pricing Push: Starting And Ending With Insulin?
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.
Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform
Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.